I
Isamu Okamoto
Researcher at Kyushu University
Publications - 458
Citations - 25482
Isamu Okamoto is an academic researcher from Kyushu University. The author has contributed to research in topics: Lung cancer & Epidermal growth factor receptor. The author has an hindex of 64, co-authored 413 publications receiving 19982 citations. Previous affiliations of Isamu Okamoto include Emory University & Kumamoto University.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study.
Haruko Daga,Koji Takeda,Hideaki Okada,Masaki Miyazaki,Shinya Ueda,Hiroyasu Kaneda,Isamu Okamoto,Kiyotaka Yoh,Koichi Goto,Koichi Konishi,Akiko Sarashina,Nobutaka Yagi,Kiyomi Mera,Rolf Kaiser,Kazuhiko Nakagawa +14 more
TL;DR: Nintedanib is a potent, orally bio-available triple angiokinase inhibitor that targets VEGFRs, PDGFRs and FGFRs as well as RET and Flt3, and the open-label phase I part of this ph...
Journal ArticleDOI
Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Kazuko Sakai,Takayuki Takahama,Mototsugu Shimokawa,Koichi Azuma,Masayuki Takeda,Terufumi Kato,Haruko Daga,Isamu Okamoto,Hiroaki Akamatsu,Shunsuke Teraoka,Akira Ono,Tatsuo Ohira,Toshihide Yokoyama,Nobuyuki Yamamoto,Kazuhiko Nakagawa,Kazuto Nishio +15 more
TL;DR: Monitoring ctDNA monitoring for sensitizing EGFR mutations at C4 is suitable for predicting the treatment outcomes in NSCLC patients receiving osimertinib, suggesting that osimERTinib targeted both T790M mutation‐positive tumors and tumors with sensitizingEGFR mutations.
Journal ArticleDOI
Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.
Katsuyuki Kiura,Kiyotaka Yoh,Nobuyuki Katakami,Naoyuki Nogami,Kazuo Kasahara,Toshiaki Takahashi,Isamu Okamoto,Mireille Cantarini,Rachel Hodge,Hirohiko Uchida +9 more
TL;DR: Osimertinib provided clinical benefit with a manageable safety profile in patients with pretreated EGFR T790M mutation‐positive non‐small cell lung cancer (NSCLC) whose screening EG FR T790m mutation‐ positive status was determined from cytology samples.
Journal ArticleDOI
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Kimio Yonesaka,Eiji Iwama,Hidetoshi Hayashi,Shinichiro Suzuki,Ryoji Kato,Satomi Watanabe,Takayuki Takahama,Junko Tanizaki,Kaoru Tanaka,Masayuki Takeda,Kazuko Sakai,Koichi Azuma,Yasutaka Chiba,Shinji Atagi,Kazuto Nishio,Isamu Okamoto,Kazuhiko Nakagawa +16 more
TL;DR: Soluble heregulin potentially correlates with resistance to EG FR-TKIs but not 2nd-generation EGFR-TkIs in patients with EGFR -mutant NSCLC, and Cox proportional hazards model indicated a trend toward resistance against 1st-generation EGFs but not against 2 second- generation EGFR
Journal ArticleDOI
The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors
Kazuki Takada,Mototsugu Shimokawa,Shinkichi Takamori,Shinichiro Shimamatsu,Fumihiko Hirai,Yuki Ono,Tetsuzo Tagawa,Tatsuro Okamoto,Motoharu Hamatake,Isamu Okamoto,Masaki Mori +10 more
TL;DR: PPI use was associated with poor clinical outcomes in patients with postoperative recurrence of NSCLC who were receiving ICIs, and PPI non-use was an independent predictor of disease control.